Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rai

Showing results (451-460 of 543) with videos related to

Pageof 55
Sort By:
The Journal of Clinical Investigation|April 2, 2004
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemiaFabio Ghiotto, Franco Fais, Angelo Valetto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemiaSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.
Experimental Eye Research|January 18, 2016
Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degenerationNathan G Lambert, Xiaohui Zhang, Ruju R Rai, et al.
Annals of Internal Medicine|April 15, 1989
Chronic lymphocytic leukemia: recommendationsB D Cheson, J M Bennett, K R Rai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Leukemia|December 6, 2017
Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purityS Marsilio, H Khiabanian, G Fabbri, et al.
Leukemia|November 23, 2024
CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survivalGerardo Ferrer, Florencia Palacios, Pui Yan Chiu, et al.
Leukemia|July 24, 2009
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemiaA Osterborg, R Foà, R F Bezares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.
Blood|October 1, 2009
In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemiaCarlo Calissano, Rajendra N Damle, Gregory Hayes, et al.
Pageof 55

Showing results (451-460 of 543) with videos related to

Sort By:
Pageof 55
The Journal of Clinical Investigation|April 2, 2004
Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemiaFabio Ghiotto, Franco Fais, Angelo Valetto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2007
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemiaSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.
Experimental Eye Research|January 18, 2016
Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degenerationNathan G Lambert, Xiaohui Zhang, Ruju R Rai, et al.
Annals of Internal Medicine|April 15, 1989
Chronic lymphocytic leukemia: recommendationsB D Cheson, J M Bennett, K R Rai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101Thomas S Lin, Kathleen A Donohue, John C Byrd, et al.
Leukemia|December 6, 2017
Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purityS Marsilio, H Khiabanian, G Fabbri, et al.
Leukemia|November 23, 2024
CLL crosstalk with naïve T cells enhances the differentiation of IL-22-producing T cells and CLL -cell survivalGerardo Ferrer, Florencia Palacios, Pui Yan Chiu, et al.
Leukemia|July 24, 2009
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemiaA Osterborg, R Foà, R F Bezares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersenSusan O'Brien, Joseph O Moore, Thomas E Boyd, et al.
Blood|October 1, 2009
In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemiaCarlo Calissano, Rajendra N Damle, Gregory Hayes, et al.
Pageof 55